Cardiac Arrythmias
Educational clinical summary of Cardiac Arrythmias for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.
Overview
Definition
Cardiac arrhythmias are disorders of the heart rhythm characterized by abnormal impulse formation (automaticity or triggered activity) or abnormal impulse conduction (reentry), resulting in a heart rate that is too slow (bradycardia, $<60$ bpm), too fast (tachycardia, $>100$ bpm), or irregular.
Epidemiology
Arrhythmias are common, with prevalence increasing significantly with age and underlying heart disease.
* Atrial Fibrillation (AFib): The most common sustained arrhythmia, affecting 1–2% of the general population, rising to over 10% in those over 80 years old.
* Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF): A leading cause of sudden cardiac death (SCD), accounting for approximately 300,000 deaths annually in the US.
* Bradyarrhythmias (Sick Sinus Syndrome, AV Block): Increase with age, often requiring pacemaker implantation in older adults.
Classification
Arrhythmias are typically classified based on their site of origin and rate:
| Origin Location |
Fast Rate (Tachycardia >100 bpm) |
Slow Rate (Bradycardia <60 bpm) |
| Supraventricular |
AFib, Atrial Flutter, AVNRT, AVRT (WPW), Sinus Tachycardia, MAT |
Sinus Bradycardia, Sick Sinus Syndrome |
| Atrioventricular (AV) Node/Junction |
Junctional Tachycardia |
AV Block (1st, 2nd, 3rd Degree) |
| Ventricular |
VT (monomorphic, polymorphic, Torsades de Pointes), VF |
Idioventricular Rhythm, Advanced AV Block |
Pathophysiology
Mechanism
The fundamental mechanisms driving arrhythmias are grouped into three categories:
- Abnormal Automaticity: Cells that normally do not generate rhythm (e.g., atrial or ventricular myocytes) begin to fire autonomously (e.g., digitalis toxicity, catecholamine excess).
- Triggered Activity: Action potential (AP) is prematurely triggered by events following depolarization:
- Early Afterdepolarizations (EADs): Occur during Phase 2 or 3 of the AP; often associated with long QT interval and Torsades de Pointes.
- Delayed Afterdepolarizations (DADs): Occur after completion of repolarization (Phase 4); associated with high intracellular calcium (e.g., catecholaminergic polymorphic VT).
- Reentry (The most common mechanism): Requires three conditions:
- Presence of an anatomical or functional circuit.
- Unidirectional block within part of the circuit.
- Conduction time around the circuit is slow enough that the tissue initially blocked has recovered excitability (resulting in continuous, repetitive activation).
Risk Factors
- Structural Heart Disease: Myocardial Infarction (MI), Heart Failure (HF) (reduced ejection fraction), Cardiomyopathies (hypertrophic, dilated), Valvular heart disease.
- Electrolyte Disturbances: Hypokalemia, hyperkalemia, hypomagnesemia, hypocalcemia.
- Autonomic Tone: High sympathetic tone (stress, fever, exercise, hyperthyroidism) or high vagal tone.
- Ischemia/Hypoxia: Coronary artery disease, severe lung disease.
- Genetics: Channelopathies (e.g., Long QT Syndrome, Brugada Syndrome), familial cardiomyopathies.
- Drugs: Proarrhythmic agents (Type IA and IC antiarrhythmics), QT-prolonging drugs (e.g., macrolides, fluoroquinolones, certain antifungals).
- Environmental: Alcohol consumption (Holiday Heart Syndrome), stimulants (caffeine, cocaine).
Protective Factors
- Optimal Blood Pressure Control: Prevents structural remodeling.
- Treatment of Underlying Heart Disease: Beta-blockers in HF, revascularization in CAD.
- Avoidance of Cardiotoxins: Limiting alcohol, avoiding illicit drugs.
- Electrolyte Homeostasis: Maintaining serum potassium (K+) above 4.0 mEq/L and magnesium (Mg2+) > 2.0 mg/dL, especially in high-risk patients.
- Healthy Lifestyle: Regular exercise, weight management (BMI <25), avoiding sleep apnea.
Clinical Presentation
Signs and Symptoms
| Presentation Category |
Examples |
Significance |
| Cardinal Features |
Palpitations (sense of skipped, pounding, or rapid beats), Fatigue, Dyspnea, Pre-syncope/Syncope |
Most common patient complaints. Syncope suggests a hemodynamically significant or potentially lethal arrhythmia. |
| Early Signs |
Transient lightheadedness, Anxiety, Mild chest discomfort, Noticeable change in heart rhythm. |
Often precede sustained or severe events. |
| Advanced Signs |
Acute Heart Failure (pulmonary edema), Hypotension, Angina (due to inadequate coronary perfusion), Diaphoresis, Altered mental status. |
Indicate hemodynamic instability requiring urgent intervention. |
| Atypical Presentations |
Silent Arrhythmia (e.g., asymptomatic AFib), Stroke (first manifestation of AFib), Gastrointestinal symptoms (nausea/vomiting due to low perfusion). |
Important to recognize, especially in geriatric or diabetic populations. |
Physical Examination
| Examination Area |
Findings Specific to Arrhythmias |
| Inspection |
Signs of heart failure (JVD, ankle edema), Digital clubbing (chronic hypoxia), Pacemaker scar. |
| Palpation |
Pulse: Irregularly irregular pulse (classic AFib); Weak, thready pulse (low cardiac output); Bradycardia or Tachycardia. Precordium: Sternal lift (RVH), Displacement of PMI (cardiomegaly). |
| Auscultation |
Heart Sounds: Variable S1 intensity (AFib, 3rd-degree AV block due to AV dissociation); S4 gallop (LV hypertrophy); Murmurs indicating underlying valve disease. Lungs: Rales/crackles (pulmonary edema from acute HF). |
| Special Tests |
Blood Pressure: Pulsus paradoxus (rarely associated with restrictive physiology leading to arrhythmias), Significant hypotension. |
Diagnostic Approach
History Taking
| Key Questions |
Clinical Goal |
| Symptom Characteristics |
Onset/cessation (abrupt vs. gradual), frequency, duration, precipitating factors (exercise, stress, caffeine), relieving factors. |
| Syncope/Pre-syncope |
Position (standing/lying down), warnings, associated events (seizure, injury). |
| Comorbidities |
History of MI/CAD, HF, Diabetes, Hyper/Hypothyroidism, Sleep Apnea. |
| Medication Review |
QT-prolonging drugs, antiarrhythmics, stimulants, supplements. |
| Family History |
Sudden cardiac death (SCD) before age 50, Syncope, Pacemakers. |
Red Flags
- Syncope or near-syncope during exertion.
- Sustained chest pain or hemodynamic instability during an event.
- Family history of sudden cardiac death.
- Arrhythmias occurring in the setting of severe structural heart disease (Ejection Fraction <35%).
Laboratory Tests
| Test Category |
Tests |
Clinical Relevance |
| First-Line |
Comprehensive Metabolic Panel (electrolytes, especially K+, Mg2+), Renal function (Cr), Thyroid Stimulating Hormone (TSH), Troponin (if ischemia suspected). |
Identify reversible causes (electrolyte imbalance) and rule out acute coronary syndrome. |
| Confirmatory |
B-type Natriuretic Peptide (BNP) (if acute HF suspected), Toxicology screen (if drug use suspected). |
Quantify heart failure or identify exogenous causes. |
| Monitoring |
INR/PTT (for anticoagulation), Digoxin levels, Antiarrhythmic drug levels (e.g., Amiodarone TSH/LFTs). |
Ensure therapeutic drug levels and monitor for toxicity. |
Diagnostic Modalities
Electrocardiogram (ECG)
The 12-lead ECG is the essential first step.
* Routine ECG: Measures rate, rhythm, intervals (PR, QRS, QT), and identifies hypertrophy or previous MI.
* Specific findings: Delta wave (WPW), prolonged QT (LQTS), coved ST elevation (Brugada).
| Modality |
Indication & Duration |
Purpose |
| Recommended: Continuous Monitoring |
Holter Monitor (24-48 hours) |
For frequent, daily symptoms. |
| Recommended: Event Monitoring |
Mobile Cardiac Telemetry (up to 30 days) |
For infrequent (< monthly) symptoms. Patient-activated or auto-triggered. |
| Recommended: Implantable Loop Recorder (ILR) |
Up to 3 years |
For very infrequent symptoms, unknown syncope etiology, or post-SCD risk stratification. |
| Recommended: Exercise Stress Test |
Symptoms triggered by exertion. |
Evaluate rate-related block, exercise-induced VT, or chronotropic incompetence. |
| Advanced: Electrophysiology Study (EPS) |
Pre-ablation procedure, unexplained syncope with structural heart disease, risk stratification (e.g., LVEF <35%). |
Precise mapping of conduction pathways, induction of clinical arrhythmias, guiding ablation, risk assessment. |
Management
Acute Management (ACLS/PALS Guidelines)
The immediate goal is to determine if the patient is stable or unstable. Unstable patients exhibit signs of inadequate cardiac output (hypotension, shock, acute heart failure, ischemic chest pain, altered mental status).
1. Unstable Patients (Immediate Emergent Management)
| Arrhythmia |
Intervention |
Action |
| Tachycardia (Narrow or Wide QRS) |
Synchronized Cardioversion |
Deliver immediate, synchronized shock (typically 100-200 J biphasic). Sedate patient if possible. |
| Ventricular Fibrillation (VF) or Pulseless VT |
Defibrillation (Immediate) |
Deliver immediate, unsynchronized shock (200 J biphasic or 360 J monophasic). Initiate CPR immediately afterward. |
| Bradycardia (Symptomatic) |
Pacing |
1. Transcutaneous Pacing (TCP): Initiate immediately. 2. Atropine (0.5 mg IV bolus; max 3 mg) while awaiting TCP/transvenous access. 3. Dopamine or Epinephrine infusion if Atropine fails. |
| Asystole |
CPR & Epinephrine |
Initiate CPR. Epinephrine 1 mg IV/IO every 3–5 minutes. Do NOT pace. |
2. Stable Tachycardia Management
| Arrhythmia Type |
First-Line Intervention |
Specific Drug/Dose |
| Stable Narrow Complex (SVT, AVNRT) |
Vagal Maneuvers |
Carotid massage, Valsalva. |
|
Adenosine |
6 mg IV push, followed rapidly by saline flush. If no effect, 12 mg bolus (max two doses). (Caution in asthma/transplanted heart). |
|
If Adenosine Fails/CI: |
Verapamil or Diltiazem IV. |
| Stable Atrial Fibrillation/Flutter (Rate Control) |
Rate Control Agents |
Beta-blockers (e.g., Metoprolol 2.5–5 mg IV) or Calcium Channel Blockers (Diltiazem 0.25 mg/kg IV). |
| Stable Wide Complex Tachycardia (VT) |
Amiodarone or Procainamide |
Amiodarone: 150 mg IV over 10 minutes, followed by infusion. OR Procainamide: 20–50 mg/min infusion (max 17 mg/kg). |
Chronic Management
Pharmacological Management
| Arrhythmia |
Primary Goal |
First-Line Drugs |
Dosage/Specific Point |
| Atrial Fibrillation/Flutter |
Stroke Prevention (Use CHA2DS2-VASc score) |
NOACs (Apixaban, Rivaroxaban, Dabigatran) or Warfarin. |
Target INR 2.0–3.0 for Warfarin. NOACs preferred unless mechanical valve or severe renal failure. |
|
Rate Control |
Beta-blockers (Metoprolol, Atenolol) or Non-DHP CCBs (Diltiazem, Verapamil). |
Target resting HR <80 bpm (or <110 bpm if asymptomatic). |
|
Rhythm Control |
Flecainide, Propafenone (if no structural heart disease); Dofetilide, Sotalol, Amiodarone (if structural heart disease/HF). |
Amiodarone requires baseline LFTs, TSH, and chest X-ray. |
| Ventricular Tachycardia (Non-Sustained) |
Risk Reduction |
Beta-blockers (always first line, especially post-MI). |
|
| PVCs/PACs (Symptomatic) |
Symptom Control |
Beta-blockers. (Antiarrhythmics only if frequent and causing tachycardia-induced cardiomyopathy). |
|
Non-pharmacological Management
| Treatment |
Indication |
Mechanism |
| Catheter Ablation |
Symptomatic AFib refractory to antiarrhythmics, AVNRT/AVRT, Refractory VT (especially idiopathic VT). |
Destroys the small area of tissue responsible for the arrhythmia (reentry circuit, automatic focus). |
| Implantable Cardioverter-Defibrillator (ICD) |
Primary Prevention: LVEF $\le 35\%$ due to ischemic heart disease or non-ischemic cardiomyopathy (NYHA Class II/III symptoms). Secondary Prevention: Survivors of SCD due to VF or unstable VT. |
Delivers high-energy countershock to terminate VT/VF. |
| Permanent Pacemaker (PPM) |
Symptomatic bradyarrhythmias (Sick Sinus Syndrome, 2nd or 3rd degree AV block), Biventricular pacing (CRT) for HF with LVEF $\le 35\%$ and LBBB. |
Provides electrical impulses to ensure adequate heart rate. |
| Lifestyle Modification |
All arrhythmias. |
Weight loss (for AFib), reduction in alcohol/caffeine, sleep apnea treatment, exercise. |
Treatment Algorithms (Example: Stable AFib)
- Assess Hemodynamics: Stable vs. Unstable. (If unstable, proceed directly to synchronized cardioversion.)
- Anticoagulation: Calculate CHA2DS2-VASc score.
- Score $\ge 2$ in men ($\ge 3$ in women): Initiate DOAC (NOAC) or Warfarin.
- Rate Control vs. Rhythm Control Decision:
- Rate Control favored if: Asymptomatic or mild symptoms, age >65, multiple comorbidities.
- Rhythm Control favored if: Highly symptomatic, younger patient, difficulty achieving rate control, tachycardia-induced cardiomyopathy.
- Rate Control: Aim for resting HR <80 bpm. Use beta-blockers or non-DHP CCBs.
- Rhythm Control: Consider catheter ablation if recurrence is high desire or first-line drug therapy is insufficient.
Refractory Cases
- Refractory VT/VF: EPS guided substrate modification, concomitant ICD placement, dual antiarrhythmic therapy, or surgical ablation (reserved for highly complex cases).
- Refractory AFib: Repeat ablation procedures (pulmonary vein isolation + substrate modification), surgical MAZE procedure (often combined with structural repair).
- Pacemaker Syndrome: Reprogramming pacing mode (e.g., VVIR to DDD), optimizing AV delay.
Complications
Common
- Heart Failure: Tachycardia-induced cardiomyopathy (due to prolonged high ventricular rates) or loss of atrial kick in severe bradycardia.
- Thromboembolism: Ischemic stroke (especially AFib, increasing risk 5-fold), systemic embolism.
- Proarrhythmia: Antiarrhythmic drugs themselves causing new or worse arrhythmias (e.g., QT prolongation leading to Torsades de Pointes).
Serious
- Sudden Cardiac Death (SCD): Often caused by sustained VT or VF.
- Cardiogenic Shock: Related to critically low cardiac output during severe tachyarrhythmia or severe bradyarrhythmia.
Long-term
- Cognitive Decline/Vascular Dementia: Associated with chronic AFib, possibly due to microemboli.
- Need for Device Therapy: Chronic dependency on pacemakers or ICDs, risk of lead fracture/infection.
Prognosis
Factors Affecting Outcome
- Presence of Structural Heart Disease (Worst Prognosis): Arrhythmias in the setting of severe LVEF reduction carry a much higher mortality risk.
- Arrhythmia Type: VT/VF carries the highest immediate risk.
- Hemodynamic Tolerance: Patients who are hypotensive or syncope-prone have poorer outcomes without intervention.
- Reversibility/Treatability: Arrhythmias due to reversible causes (electrolytes, drugs) have excellent prognosis once corrected.
Survival
- AFib: Patients with AFib have a modestly decreased overall survival, primarily due to associated structural heart disease and higher risk of stroke.
- Post-MI: VT/VF risk is highest in the first year post-MI, particularly with LVEF <30%. ICD implantation significantly improves survival in these high-risk primary and secondary prevention groups.
Prevention
Primary Prevention
- Optimize Cardiovascular Health (CV Risk Factor Management): Treating hypertension, diabetes, and hyperlipidemia.
- Minimize Cardiotoxins: Strict limits on alcohol and avoidance of stimulant drugs.
- Identify and Manage Channelopathies: Genetic testing and prophylactic beta-blockers (e.g., Nadolol/Propranolol for LQTS).
Secondary Prevention
- ICD Implantation: For surviving VT/VF or high-risk patients (LVEF $\le 35\%$).
- Antiarrhythmic Drugs: Use of Class I or III agents after cardioversion to maintain sinus rhythm in AFib.
- Anticoagulation: Mandatory for AFib according to CHA2DS2-VASc score to prevent recurrent stroke.
Special Populations
Pediatric
- Diagnosis and Management: Often present with non-specific symptoms (poor feeding, pallor, fatigue).
- Common Arrhythmias: SVT (most common), Long QT Syndrome, and arrhythmias associated with congenital heart disease repair (e.g., Fontan circulation).
- Dosages: Require weight-based dosing (e.g., Adenosine 0.1 mg/kg first dose).
Geriatric
- Atypical Presentation: Arrhythmias often present as confusion, fatigue, or falls rather than classic palpitations.
- Medication Sensitivity: Highly susceptible to drug toxicity (e.g., Digoxin, Amiodarone) due to reduced renal and hepatic clearance. Start low, go slow.
- Bradyarrhythmias: Sick Sinus Syndrome and nodal disease are common, frequently necessitating PPM.
Pregnancy
- Initial Approach: Vagal maneuvers are first-line.
- Safety: Beta-blockers (labetalol, metoprolol, propranolol) are typically safe. Adenosine is safe for acute SVT termination.
- Avoid: Amiodarone (risk of fetal thyroid toxicity), Dofetilide, and Warfarin (teratogenic in the first trimester; switch to LMWH). Cardioversion is safe if medically necessary.
Comorbidities
- Heart Failure (HFrEF): Antiarrhythmics are restricted (Class IC agents contraindicated). Amiodarone, Sotalol, and Dofetilide are generally considered safe. Beta-blockers (Carvedilol, Metoprolol Succinate, Bisoprolol) are cornerstone therapy.
- COPD/Asthma: Beta-blockers should be used cautiously (use beta-1 selective agents like Metoprolol). Avoid non-selective agents unless absolutely necessary.
- Renal Impairment: Adjust dosages for many antiarrhythmics (e.g., Digoxin, Sotalol, NOACs).
Clinical Pearls
Diagnostic
- Irregularly Irregular Pulse: Virtually pathognomonic for Atrial Fibrillation (excluding multifocal atrial tachycardia or frequent premature beats).
- Narrow Complex Tachycardia (SVT/P-wave analysis): Look for P waves buried within or immediately following the QRS to differentiate AVNRT vs. AVRT vs. Atrial Tachycardia.
- Wide Complex Tachycardia (WCT): Assume VT until proven otherwise. Use the Brugada or Vereckei criteria to differentiate VT from SVT with aberrancy.
Treatment
- Cardioversion Timing: In AFib of unknown duration or >48 hours, anticoagulation for 3 weeks prior to elective cardioversion is mandatory, unless guided by a negative Transesophageal Echocardiogram (TEE).
- Torsades de Pointes (TdP): Main treatment is IV Magnesium (2 g bolus), withdrawal of QT-prolonging agents, and temporary overdrive pacing/Isoproterenol infusion to shorten the QT interval.
- Digoxin Toxicity: Treat with Digoxin immune Fab (Digibind).
Pitfalls
- Using AV Nodal Blockers in WPW: Giving Adenosine, CCBs, or Digoxin to a patient with Atrial Fibrillation and WPW (pre-excitation) can block the AV node and funnel all impulses down the accessory pathway, potentially leading to Ventricular Fibrillation (VF). Use Procainamide or synchronized cardioversion.
- Starting Class IC Agents (Flecainide, Propafenone) in Structural Disease: These drugs are contraindicated post-MI or in patients with significant LV dysfunction due to increased mortality risk (CAST trial findings).
Recent Updates
Guidelines
- 2023 ACC/AHA/HRS Guideline for the Diagnosis and Management of AFib: Stronger emphasis on Weight Reduction and Lifestyle Modification as essential components of AFib therapy. Recommends defining management around the "4 Pillars": Anticoagulation, Symptom Control (rate/rhythm), Risk Factor Modification, and Comorbidity Management.
Evidence
- EAST-AFNET 4 Trial: Showed that early rhythm control (ablation or antiarrhythmics) within one year of AFib diagnosis significantly reduced the composite outcome of cardiovascular death, stroke, or heart failure hospitalization compared to delayed rhythm control.
Controversies
- LAA Occlusion: While LAA (Left Atrial Appendage) occlusion devices are available, the role of these devices versus long-term NOACs remains debated, primarily reserved for patients with absolute contraindications to long-term anticoagulation.
- Ideal Rate Control Target: The AFFIRM trial suggested a lenient rate control target (HR <110 bpm) was non-inferior to strict control. Current guidelines allow the lenient target if the patient is asymptomatic and does not show signs of tachycardia-induced cardiomyopathy.
Key References
Guidelines
- 2023 ACC/AHA/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation.
- 2020 AHA/ACC Guideline for the Management of Patients with Supraventricular Tachycardia.
- 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
- Advanced Cardiac Life Support (ACLS) Guidelines (Current iteration).
Disclaimer: This information is for educational purposes and should not replace clinical judgment or consultation with a qualified medical professional. Treatment protocols, dosages, and diagnostic criteria are subject to change based on evolving medical evidence and individual patient circumstances.
